Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement in its entirety for any reason upon ninety (90) days prior written notice to Licensor. Upon termination in accordance with this Section 7.2, the licenses granted by Licensor pursuant to Article 2 shall terminate in its entirety. Licensee shall remain obligated for all payments due at the time of such notice and for any continuing obligations otherwise surviving and owed under this Agreement pursuant to Section 7.9.
Appears in 5 contracts
Samples: Non Exclusive License Agreement, Non Exclusive License Agreement (Allakos Inc.), Non Exclusive License Agreement (Allakos Inc.)
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement in its entirety for any reason at will, with or without cause, upon ninety (90) days prior written notice to Licensor. Upon , provided that such termination in accordance with this shall be effective no earlier than the first anniversary of the date upon which Licensee made the last payment to Licensor under Section 7.2, the licenses granted by Licensor pursuant to Article 2 shall terminate in its entirety. Licensee shall remain obligated for all payments due at the time of such notice and for any continuing obligations otherwise surviving and owed under this Agreement pursuant to Section 7.95.1(i) below.
Appears in 1 contract
Samples: License and Supply Agreement (Synutra International, Inc.)
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement in its entirety for any reason upon ninety *** (90***) days prior written notice to Licensor. Upon termination in accordance with this Section 7.2, the licenses granted by Licensor pursuant to Article 2 shall terminate in its entiretyterminate. Licensee shall remain obligated for all payments due at the time of such notice and for any continuing obligations otherwise surviving and owed under this Agreement pursuant to Section 7.9.
Appears in 1 contract
Samples: Non Exclusive License Agreement (Five Prime Therapeutics Inc)